Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?
- PMID: 27098448
- PMCID: PMC8031695
- DOI: 10.1111/jch.12832
Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?
Conflict of interest statement
The authors report no specific funding in relation to this research and no conflicts of interest to disclose.
Comment in
-
Response to Stavropoulos.J Clin Hypertens (Greenwich). 2016 Oct;18(10):1074-1075. doi: 10.1111/jch.12831. Epub 2016 Apr 21. J Clin Hypertens (Greenwich). 2016. PMID: 27098365 Free PMC article. No abstract available.
Comment on
-
Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension.J Clin Hypertens (Greenwich). 2016 Jan;18(1):43-52. doi: 10.1111/jch.12747. Epub 2015 Dec 10. J Clin Hypertens (Greenwich). 2016. PMID: 26663712 Free PMC article. Clinical Trial.
References
-
- Imprialos KP, Sarafidis PA, Karagiannis AI. Sodium‐glucose cotransporter‐2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? J Hypertens. 2015;33:2185–2197. - PubMed
-
- Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta‐analysis. J Hypertens. 2004;22:435–445. - PubMed
-
- Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56:780–800. - PubMed
-
- Weber MA, Jamerson K, Bakris GL, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013;381:537–545. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
